Overview

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Status:
Completed
Trial end date:
2009-04-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .
Phase:
Phase 3
Details
Lead Sponsor:
Amgen